Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized study of YL201 versus investigator's choice chemotherapy in recurrent or metastatic nasopharyngeal carcinoma after PD-(L)1 inhibitor and at least two prior chemotherapy lines
CTR20244561Phase 3Active
- Sponsor
- MediLink Therapeutics
- Start
- Dec 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of YL201 in nasopharyngeal carcinoma (NPC), sponsored by MediLink Therapeutics. Started Dec 2024; status: active.
02
Drugs
YL201
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on CTR20244561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244561.